Last Price$137.11.5%
Market Cap$237.5B
LTM Cash & Cash Equivalents
$7,616.0M
YoY Growth
+10.4%
3Y CAGR
-8.1%
5Y CAGR
+14.6%
Stock quality & Intrinsic value
7/10
29.8% undervalued
Abbott Laboratories Cash & Cash Equivalents
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Cash Equivalents | $2,893.7M | $521.2M | $2,456.4M | $4,112.0M | $8,809.3M | $3,648.4M | $6,812.8M | $10.8B | $3,475.0M | $4,063.0M | $5,001.0M | $18.6B | $9,407.0M | $3,844.0M | $3,860.0M | $6,838.0M | $9,799.0M | $9,882.0M | $6,896.0M | $7,616.0M |
Overvalued or undervalued?
Check the intrinsic value for ABT
and see if it's the right time to invest.
Abbott Laboratories (ABT) Cash & Cash Equivalents comparison analysis
General
LTM Cash & Cash Equivalents
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Abbott LaboratoriesABT
$7,616.0M
10.4%
(8.1%)
14.6%
Median Peer Set
$998.6M
15.9%
(0.2%)
8.7%
Stryker CorporationSYK
$3,652.0M
22.9%
7.4%
(3.4%)
Edwards Lifesciences CorporationEW
$3,045.2M
166.2%
52.3%
20.9%
Koninklijke Philips N.V.PHG
$2,486.2M
20.5%
1.4%
11.0%
Medtronic plcMDT
$1,240.0M
(23.6%)
(29.1%)
(19.7%)
Align Technology, Inc.ALGN
$1,043.9M
11.4%
(1.7%)
13.7%
Insulet CorporationPODD
$953.4M
46.5%
6.4%
20.4%
DexCom, Inc.DXCM
$606.1M
7.0%
(16.8%)
6.3%
Zimmer Biomet Holdings, Inc.ZBH
$525.5M
26.4%
11.6%
(3.2%)
Boston Scientific CorporationBSX
$414.0M
(52.1%)
(40.1%)
13.8%
STERIS plcSTE
$155.2M
(20.7%)
(24.4%)
(4.9%)
ABT key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 22,337.8 13.5% | 22,476.3 0.6% | 25,914.2 15.3% | 29,527.6 13.9% | 30,765.0 4.2% | 35,167.0 14.3% | 38,851.0 10.5% | 39,874.0 2.6% | 21,848.0 (45.2%) | 20,247.0 (7.3%) | 20,405.0 0.8% | 20,853.0 2.2% | 27,390.0 31.3% | 30,578.0 11.6% | 31,904.0 4.3% | 34,608.0 8.5% | 43,075.0 24.5% | 43,653.0 1.3% | 40,109.0 (8.1%) | 41,950.0 4.6% |
| Cost of Goods Sold (COGS) | 10,641.1 | 9,815.1 | 11,422.0 | 12,612.0 | 13,209.0 | 14,665.0 | 15,541.0 | 15,120.0 | 10,040.0 | 9,218.0 | 8,747.0 | 9,024.0 | 12,337.0 | 12,706.0 | 13,231.0 | 15,003.0 | 18,537.0 | 19,142.0 | 17,975.0 | 18,706.0 |
% margin | 11,696.7 52.4% | 12,661.2 56.3% | 14,492.2 55.9% | 16,915.5 57.3% | 17,556.0 57.1% | 20,502.0 58.3% | 23,310.0 60.0% | 24,754.0 62.1% | 11,808.0 54.0% | 11,029.0 54.5% | 11,658.0 57.1% | 11,829.0 56.7% | 15,053.0 55.0% | 17,872.0 58.4% | 18,673.0 58.5% | 19,605.0 56.6% | 24,538.0 57.0% | 24,511.0 56.1% | 22,134.0 55.2% | 23,244.0 55.4% |
| Operating Expenses | 7,317.3 | 8,605.0 | 9,913.6 | 11,124.4 | 11,150.0 | 14,101.0 | 17,558.0 | 16,381.0 | 9,179.0 | 8,430.0 | 8,791.0 | 8,644.0 | 13,327.0 | 14,222.0 | 14,141.0 | 14,248.0 | 16,113.0 | 16,149.0 | 15,656.0 | 16,419.0 |
| Research & Development Expenses (R&D) | 1,821.2 | 2,255.3 | 2,505.6 | 2,688.8 | 2,744.0 | 3,725.0 | 4,802.0 | 4,322.0 | 1,452.0 | 1,345.0 | 1,405.0 | 1,422.0 | 2,235.0 | 2,300.0 | 2,440.0 | 2,420.0 | 2,742.0 | 2,888.0 | 2,741.0 | 2,844.0 |
| Selling, General & Administrative Expenses (SG&A) | 5,496.1 | 6,349.7 | 7,408.0 | 8,435.6 | 8,406.0 | 10,376.0 | 12,756.0 | 12,059.0 | 6,936.0 | 6,530.0 | 6,785.0 | 6,672.0 | 9,117.0 | 9,744.0 | 9,765.0 | 9,696.0 | 11,324.0 | 11,248.0 | 10,949.0 | 11,697.0 |
% margin | 4,362.3 19.5% | 2,042.2 9.1% | 4,578.5 17.7% | 5,693.8 19.3% | 6,236.0 20.3% | 6,088.0 17.3% | 5,752.0 14.8% | 8,085.0 20.3% | 2,629.0 12.0% | 2,599.0 12.8% | 2,867.0 14.1% | 3,185.0 15.3% | 1,726.0 6.3% | 3,650.0 11.9% | 4,532.0 14.2% | 5,357.0 15.5% | 8,425.0 19.6% | 8,362.0 19.2% | 6,478.0 16.2% | 6,825.0 16.3% |
| Interest Income | 0.0 | 0.0 | 0.0 | 201.2 | 137.8 | 105.5 | 85.2 | 79.2 | 67.0 | 77.0 | 105.0 | 99.0 | 124.0 | 105.0 | 94.0 | 46.0 | 43.0 | 183.0 | 385.0 | 344.0 |
| Interest Expense | 153.7 | 292.3 | 593.1 | 528.5 | 382.0 | 553.1 | 530.1 | 513.0 | 90.0 | 73.0 | 58.0 | 332.0 | 780.0 | 721.0 | 576.0 | 500.0 | 490.0 | 375.0 | 637.0 | 559.0 |
| Pre-tax Income | 4,619.9 | 2,276.4 | 4,469.6 | 5,856.3 | 7,194.0 | 5,713.0 | 5,199.0 | 6,263.0 | 2,521.0 | 2,518.0 | 3,183.0 | 1,413.0 | 2,231.0 | 2,873.0 | 4,077.0 | 4,968.0 | 8,211.0 | 8,306.0 | 6,664.0 | 7,013.0 |
% effective tax rate | 1,247.9 27.0% | 559.6 24.6% | 863.3 19.3% | 1,122.1 19.2% | 1,448.0 20.1% | 1,087.0 19.0% | 470.0 9.0% | 300.0 4.8% | 138.0 5.5% | 797.0 31.7% | 577.0 18.1% | 350.0 24.8% | 1,878.0 84.2% | 539.0 18.8% | 390.0 9.6% | 497.0 10.0% | 1,140.0 13.9% | 1,373.0 16.5% | 941.0 14.1% | (6,389.0) (91.1%) |
% margin | 3,372.1 15.1% | 1,716.8 7.6% | 3,606.3 13.9% | 4,880.7 16.5% | 5,745.8 18.7% | 4,626.2 13.2% | 4,728.0 12.2% | 5,963.0 15.0% | 2,576.0 11.8% | 2,284.0 11.3% | 4,423.0 21.7% | 1,400.0 6.7% | 477.0 1.7% | 2,368.0 7.7% | 3,687.0 11.6% | 4,495.0 13.0% | 7,071.0 16.4% | 6,933.0 15.9% | 5,723.0 14.3% | 13,402.0 31.9% |
| EPS | 2.17 | 1.12 | 2.34 | 3.16 | 3.72 | 2.99 | 3.01 | 3.78 | 1.66 | 1.51 | 3.00 | 0.95 | 0.27 | 1.35 | 2.07 | 2.52 | 3.97 | 3.94 | 3.30 | 7.74 |
| Diluted EPS | 2.16 | 1.12 | 2.31 | 3.13 | 3.70 | 2.97 | 3.01 | 3.75 | 1.64 | 1.50 | 2.94 | 0.94 | 0.27 | 1.34 | 2.06 | 2.50 | 3.94 | 3.91 | 3.27 | 7.67 |
% margin | 6,220.2 27.8% | 4,251.3 18.9% | 6,433.4 24.8% | 8,223.6 27.9% | 9,493.9 30.9% | 9,138.3 26.0% | 9,260.7 23.8% | 3,496.0 8.8% | 3,452.0 15.8% | 4,216.0 20.8% | 4,833.0 23.7% | 3,070.0 14.7% | 6,132.0 22.4% | 7,116.0 23.3% | 7,771.0 24.4% | 8,789.0 25.4% | 12,742.0 29.6% | 12,380.0 28.4% | 10,605.0 26.4% | 10,834.0 25.8% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Abbott Laboratories's Cash & Cash Equivalents?
As of today, Abbott Laboratories's last 12-month Cash & Cash Equivalents is $7,616.0M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Abbott Laboratories's Cash & Cash Equivalents growth rate?
Over the last year, Abbott Laboratories's Cash & Cash Equivalents growth was 10.4%. The average annual Cash & Cash Equivalents growth rates for Abbott Laboratories have been (4.2%) over the past three years, 14.6% over the past five years.
3) Is Abbott Laboratories's Cash & Cash Equivalents growth rate Good?
Over the last year, Abbott Laboratories's Cash & Cash Equivalents growth was 10.4%, which is higher than industry growth of (0.2%). It indicates that Abbott Laboratories's Cash & Cash Equivalents growth is Good.